Cerebrospinal fluid tau and amyloid-β1-42 in patients with dementia.

@article{Skillbck2015CerebrospinalFT,
  title={Cerebrospinal fluid tau and amyloid-β1-42 in patients with dementia.},
  author={Tobias Skillb{\"a}ck and Bahman Y. Farahmand and Christoffer Rosen and Niklas Mattsson and Katarina N{\"a}gga and Lena Kilander and Dorota Religa and Anders B. Wimo and Bengt Winblad and Jonathan M. Schott and Kaj Blennow and Maria Eriksdotter and Henrik Zetterberg},
  journal={Brain : a journal of neurology},
  year={2015},
  volume={138 Pt 9},
  pages={
          2716-31
        }
}
Progressive cognitive decline in combination with a cerebrospinal fluid biomarker pattern of low levels of amyloid-β1-42 and high levels of total tau and phosphorylated tau is typical of Alzheimer's disease. However, several neurodegenerative disorders may overlap with Alzheimer's disease both in regards to clinical symptoms and neuropathology. In a uniquely large cohort of dementia patients, we examined the associations of cerebrospinal fluid biomarkers for Alzheimer's disease molecular… CONTINUE READING

Citations

Publications citing this paper.
SHOWING 1-10 OF 38 CITATIONS

Cerebrospinal fluid biomarkers for Alzheimer's disease in Down syndrome

VIEW 6 EXCERPTS
CITES BACKGROUND & RESULTS
HIGHLY INFLUENCED

Precision medicine of frontotemporal dementia: from genotype to phenotype.

  • Frontiers in bioscience
  • 2018
VIEW 4 EXCERPTS
CITES BACKGROUND & RESULTS
HIGHLY INFLUENCED

A single center study: Aβ42/p-Tau181 CSF ratio to discriminate AD from FTD in clinical setting

  • Neurological Sciences
  • 2017
VIEW 10 EXCERPTS
CITES BACKGROUND, RESULTS & METHODS
HIGHLY INFLUENCED

Dementia with Lewy bodies: Challenges in the diagnosis and management.

  • The Australian and New Zealand journal of psychiatry
  • 2019
VIEW 2 EXCERPTS
CITES BACKGROUND

References

Publications referenced by this paper.
SHOWING 1-10 OF 71 REFERENCES